Drugs / GSK3145095
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03681951 | Nov 2018 → Aug 2019 | pancreatic neoplasm | GlaxoSmithKline | Terminated | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK3145095 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03681951 ↗ |
| Action | Inhibit | “inhibition of RIPK1 kinase activity” NCT03681951 ↗ |
| Route | Oral | “for oral administration” NCT03681951 ↗ |
| Target | RIPK1 | “inhibition of RIPK1 kinase activity” NCT03681951 ↗ |